HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT, HEALTH AND HUMAN SERVICES (HHS) RESTRUCTURING, MANUFACTURER-SPONSORED GENETIC SCREENING, PRIORITY REVIEW VOUCHER (PRV) EXTENSION, MEDICAID, NEWBORN SCREENING
2025 · 1st Quarter (Jan 1 - Mar 31)
BIOMARIN PHARMACEUTICAL INC.
Filed by BIOMARIN PHARMACEUTICAL INC..
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 21, 2025
- Income
- Not reported
- Expenses
- $390,000.00
- Registrant
- BIOMARIN PHARMACEUTICAL INC.
- Filing UUID
- 2a4647ed-82f9-4621-91ef-2e36492248f5
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
HR 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S 752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID REFORM
GENERAL DISCUSSIONS REGARDING TARIFFS ON PHARMACEUTICALS
GENERAL DISCUSSIONS REGARDING ORPHAN DRUG TAX CREDIT
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.